je.st
news
Tag: therapy
Industry giant to help develop firm's cancer therapy
2014-06-06 03:51:40| Biotech - Topix.net
A BIOTECH firm is set to more than double in size by the end of the year after seeing its key cancer therapy adopted by an industry giant.
Tags: industry
develop
cancer
therapy
Elekta, Michener Partnership Advances Radiation Therapy Simulation with Installation of New 3D ...
2014-05-14 06:00:00| Industrial Newsroom - All News for Today
TORONTO - Elekta, a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders, and The Michener Institute for Applied Health Sciences are enhancing the simulation experiences for the next generation of radiation therapists thanks to the addition of Clarity® to Michener's radiation therapy training suite.<br /> <br /> Clarity, installed with one of Michener's existing Elekta Synergy® treatment systems, uses sophisticated 3D ultrasound ...This story is related to the following:Simulation Software | Medical & Health Care Software
Tags: installation
partnership
therapy
simulation
Aastrom Biosciences Acquires Sanofi's Cell Therapy and Regenerative Medicine Business
2014-04-21 22:59:52| Biotech - Topix.net
Aastrom Biosciences , a developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, reported that it has entered into an agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine business for $6.5 million, with $4 million payable in cash at closing and $2.5 million payable ... (more)
Tags: business
cell
medicine
therapy
Retail Therapy: Urban Outfitters revamps Fresno store
2014-04-19 23:45:56| Apparel - Topix.net
That means the store is essentially one big sale all the time. Prices are much lower than they were before, and the store's layout and design are different.
Tags: store
retail
urban
therapy
Mercks Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection
2014-04-11 07:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Clinical Findings Support Initiation of C-EDGE Phase 3 Program WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Language: English Contact: MerckMedia Contacts:Caroline Lappetito, 267-305-7639Sarra Herzog, 201-669-6570orInvestor Contacts:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: activity
combination
patients
therapy
Sites : [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] next »